Literature DB >> 30023401

Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?

Robert W Chen1.   

Abstract

Entities:  

Year:  2018        PMID： 30023401      PMCID： PMC6035999          DOI： 10.21037/atm.2018.05.40

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  5 in total

1.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Robert Chen; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Dirk Huebner; Abraham Fong; Anas Younes
Journal:  Blood       Date:  2016-07-18       Impact factor: 22.113

2.  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Authors:  Ann S LaCasce; R Gregory Bociek; Ahmed Sawas; Paolo Caimi; Edward Agura; Jeffrey Matous; Stephen M Ansell; Howland E Crosswell; Miguel Islas-Ohlmayer; Caroline Behler; Eric Cheung; Andres Forero-Torres; Julie Vose; Owen A O'Connor; Neil Josephson; Yinghui Wang; Ranjana Advani
Journal:  Blood       Date:  2018-04-27       Impact factor: 22.113

3.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

4.  Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Authors:  Alison J Moskowitz; Paul A Hamlin; Miguel-Angel Perales; John Gerecitano; Steven M Horwitz; Matthew J Matasar; Ariela Noy; Maria Lia Palomba; Carol S Portlock; David J Straus; Tricia Graustein; Andrew D Zelenetz; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

5.  Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

Authors:  Owen A O'Connor; Jennifer K Lue; Ahmed Sawas; Jennifer E Amengual; Changchun Deng; Matko Kalac; Lorenzo Falchi; Enrica Marchi; Ithamar Turenne; Renee Lichtenstein; Celeste Rojas; Mark Francescone; Lawrence Schwartz; Bin Cheng; Kerry J Savage; Diego Villa; Michael Crump; Anca Prica; Vishal Kukreti; Serge Cremers; Joseph M Connors; John Kuruvilla
Journal:  Lancet Oncol       Date:  2017-12-21       Impact factor: 54.433
  5 in total
  1 in total

1.  HLA-DPB1 and Epstein-Barr virus gp42 protein jointly contribute to the development of Hodgkin lymphoma.

Authors:  Hongyu Li; Dan Liu; Xun Li
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.